Document Detail

Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
MedLine Citation:
PMID:  23154600     Owner:  NLM     Status:  MEDLINE    
Iron overload due to regular transfusions of packed red cells can cause multiple organ damage. Iron chelation therapy (ICT) is important in patients with aplastic anemia (AA) who require blood transfusions as supportive management. With the introduction of the oral iron chelator deferasirox, ICT has become more widely available and feasible. We studied 4 adult AA patients who had transfusion-induced iron overload and showed hematological improvement after ICT with oral deferasirox. Following deferasirox treatment, hemoglobin increased and serum ferritin levels decreased, and the patients subsequently became transfusion independent. Our experience raises the possibility of the potential benefit of ICT on hematopoiesis. Further long-term studies in larger patient cohorts are needed to clarify the effect of the restoration of hematopoiesis after iron chelation therapy.
Sung-Eun Lee; Seung-Ah Yahng; Byung-Sik Cho; Ki-Sung Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Hee-Je Kim; Seok-Goo Cho; Dong-Wook Kim; Woo-Sung Min; Chong-Won Park; Jong Wook Lee
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2012-11-15
Journal Detail:
Title:  Acta haematologica     Volume:  129     ISSN:  1421-9662     ISO Abbreviation:  Acta Haematol.     Publication Date:  2013  
Date Detail:
Created Date:  2013-02-22     Completed Date:  2013-04-10     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  72-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Aplastic / therapy*
Benzoates / therapeutic use*
Blood Transfusion / adverse effects*
Chelation Therapy
Erythrocyte Transfusion / adverse effects
Ferritins / blood
Hematopoiesis / drug effects
Immunosuppressive Agents / therapeutic use
Iron Chelating Agents / therapeutic use*
Iron Overload / drug therapy*,  etiology
Platelet Transfusion / adverse effects
Triazoles / therapeutic use*
Reg. No./Substance:
0/Benzoates; 0/Immunosuppressive Agents; 0/Iron Chelating Agents; 0/Triazoles; 7439-89-6/Iron; 9007-73-2/Ferritins; V8G4MOF2V9/deferasirox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  {blacktriangledown} Fidaxomicin for the treatment of Clostridium difficile infections.
Next Document:  Light-responsive polymer nanoreactors: a source of reactive oxygen species on demand.